08/02/2016 01:09:11 1-888-992-3836 (toll free) Free Membership Login

Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
12/01/201510:20AMDJNNovo Nordisk Buys Xoma's Diabetes Treatment
Novo Nordisk A/S has agreed to buy the global rights to Xoma Corp.'s Type 2 diabetes treatment in a deal worth up to $295 million. The price tag includes a $5 million upfront payment to Xoma and up to $290 million in milestones. Xoma also is eligible for royalties on product sales. Shares of Xoma rose 24% in recent... More...>>
12/01/20159:52AMDJNNovo Nordisk Buys Rights to Xoma's Diabetes Treatment for $295 Million
By Chelsey Dulaney Novo Nordisk A/S has agreed to buy the global rights to Xoma Corp.'s Type 2 diabetes treatment in a deal worth up to $295 million. The price tag includes a $5 million upfront payment to Xoma and up to $290 million in milestones. Xoma also is eligible for royalties on product sales. Shares of Xoma... More...>>
12/01/20158:30AMGLOBEXOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes
Novo Nordisk acquires exclusive global rights to XMetA program for the treatment of diabetes XOMA retains commercialization rights for rare disease indications $5.0 million upfront payment Agreement includes up to $290.0 million in additional potential milestone payments XOMA is entitled to tiered royalties BERKELEY, Calif... More...>>
11/12/20153:00PMGLOBEXOMA to Present at Two Upcoming Investor Conferences
BERKELEY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today members of its executive team will present at two upcoming investor conferences. The details are as follows: Jefferies Autumn 2015 Global Healthcare Conference... More...>>
11/06/201512:16PMTMFWhy XOMA Shares Are Crashing
http://www.fool.com/investing/general/2015/11/06/why-xoma-shares-are-crashing.aspx?source=eptadnlnk0000002&utm_source=advfn&utm_medium=cpc&utm_campaign=investorshub More...>>
11/05/20154:10PMGLOBEXOMA Announces the Sale of Its Manufacturing Facilities to Agenus
BERKELEY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (Nasdaq:AGEN). The transaction is expected... More...>>
11/05/20154:01PMGLOBEXOMA Provides Corporate Update and Reports Financial Results for Third Quarter 2015
BERKELEY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a corporate update and reported its financial results for the quarter ended September 30, 2015. "One hundred days ago, we announced multiple actions we would... More...>>
10/29/20151:37PMGLOBEXOMA to Announce Third Quarter 2015 Financial Results and Host Webcast on November 5
BERKELEY, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, November 5, 2015, at 4:30 p.m. Eastern time to discuss third quarter 2015 financial results and provide an... More...>>
10/26/20158:30AMGLOBEXOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
BERKELEY, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated a Phase 2 proof-of-concept study to evaluate the safety and ability to prevent hypoglycemia (dangerously low blood sugar) of a single... More...>>
10/01/20157:30AMGLOBEXOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncolo...
$37.0 million upfront payment $13.5 million loan maturity date extended to September 2020 Potential milestone payments of up to $480.0 million Royalties tiered from mid-single digits to low double digits BERKELEY, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development... More...>>
09/21/20158:46PMGLOBESHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Xoma Corporation and a Lead Pla...
NEW YORK, Sept. 11, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Xoma Corporation (NASDAQ:XOMA) securities between November 6, 2014 and July 21, 2015. Click here to... More...>>
09/21/20158:50AMPRNUSBiotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells PR Newswire NEW YORK, September 21, 2015 NEW YORK, September 21, 2015 /PRNewswire/ -- Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ:... More...>>
09/08/201510:00AMPRNUSShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against XOMA Corporation and Lead Pla...
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against XOMA Corporation and Lead Plaintiff Deadline September 22, 2015 PR Newswire NEW YORK, Sept. 8, 2015 NEW YORK, Sept. 8, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors... More...>>
08/20/20159:11AMPRNUSLaw Offices of Marc S. Henzel Announces Securities Class Action Periods
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., Aug. 20, 2015 MERION, Pa., Aug. 20, 2015 /PRNewswire/ -- The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following... More...>>
08/18/201510:30AMBWTRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors of Important Deadline in Class Action – XOMA
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015 of the important September 22, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Xoma Corporation investors... More...>>
08/03/20155:59PMPRNUSRobbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According to a Recently Filed Class Action
Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According to a Recently Filed Class Action PR Newswire SAN DIEGO and BERKELEY, Calif., Aug. 3, 2015 SAN DIEGO and BERKELEY, Calif., Aug. 3, 2015 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that a securities fraud class action... More...>>
07/30/20152:32PMPRNUSSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corpo...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation PR Newswire WILMINGTON, Del., July 30, 2015 WILMINGTON, Del., July 30, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.: Do you, or did you, own shares of XOMA Corporation (NASDAQ GM: XOMA)?... More...>>
07/30/201511:14AMBWEQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Xoma Corporation
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal... More...>>
07/23/201512:20PMBWXOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fr...
Levi & Korsinsky announces it has commenced an investigation of Xoma Corporation (NASDAQ: XOMA) concerning possible violations of federal securities laws. The investigation concerns whether Xoma Corporation and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange... More...>>
07/23/20159:50AMPRNUSOrphan Drug Designation Granted to XOMA 358 - Report on XOMA
Orphan Drug Designation Granted to XOMA 358 - Report on XOMA PR Newswire NEW YORK, July 23, 2015 NEW YORK, July 23, 2015 /PRNewswire/ -- ACI Association has initiated research coverage on XOMA Corporation (NASDAQ: XOMA). Select highlights from the internally released reports are being made available to the general public... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160208 06:09:12